Literature DB >> 32173681

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers.

Shuzo Sato1, Jumpei Temmoku1, Yuya Fujita1, Makiko Yashiro-Furuya1, Naoki Matsuoka1, Tomoyuki Asano1, Hiroko Kobayashi1, Hiroshi Watanabe1, Kiyoshi Migita1.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs, including the central nervous system. Neuropsychiatric SLE (NPSLE) is a severe and potentially fatal condition. Several factors including autoantibodies have been implicated in the pathogenesis of NPSLE. However, definitive biomarkers of NPSLE are yet to be identified owing to the complexity of this disease. This is a major barrier to accurate and timely diagnosis of NPSLE. Studies have identified several autoantibodies associated with NPSLE;some of these autoantibodies are well investigated and regarded as symptom-specific. In this review, we discuss recent advances in our understanding of the manifestations and pathogenesis of NPSLE. In addition, we describe representative symptom-specific autoantibodies that are considered to be closely associated with the pathogenesis of NPSLE.

Entities:  

Keywords:  autoantibody; biomarker; neuropsychiatric systemic lupus erythematosus; pathogenesis; symptom-specific

Mesh:

Substances:

Year:  2020        PMID: 32173681      PMCID: PMC7269884          DOI: 10.5387/fms.2020-02

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  71 in total

1.  Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins.

Authors:  M Mahler; K Kessenbrock; J Raats; R Williams; M J Fritzler; M Blüthner
Journal:  J Mol Med (Berl)       Date:  2003-03-14       Impact factor: 4.599

2.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.

Authors:  L A DeGiorgio; K N Konstantinov; S C Lee; J A Hardin; B T Volpe; B Diamond
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

Review 3.  Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  Carlo Perricone; Monica Pendolino; Marta Olivieri; Fabrizio Conti; Guido Valesini; Cristiano Alessandri
Journal:  Isr Med Assoc J       Date:  2015-03       Impact factor: 0.892

4.  Brain pathology in systemic lupus erythematosus.

Authors:  J G Hanly; N M Walsh; V Sangalang
Journal:  J Rheumatol       Date:  1992-05       Impact factor: 4.666

5.  Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.

Authors:  E S Husebye; Z M Sthoeger; M Dayan; H Zinger; D Elbirt; M Levite; E Mozes
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

6.  Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

Authors:  R M Andrade; G S Alarcón; L A González; M Fernández; M Apte; L M Vilá; G McGwin; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

Review 7.  Recent insights into the genetic basis of systemic lupus erythematosus.

Authors:  Ornella Josephine Rullo; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

8.  Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading autoimmune responses to proliferating cell nuclear antigen multiprotein complexes in lupus patients.

Authors:  Yoshinari Takasaki; Kazuhiko Kaneda; Masakazu Matsushita; Hirofumi Yamada; Masuyuki Nawata; Ran Matsudaira; Masanao Asano; Reiko Mineki; Noriko Shindo; Hiroshi Hashimoto
Journal:  Int Immunol       Date:  2004-07-19       Impact factor: 4.823

Review 9.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

10.  Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis.

Authors:  Hilda Fragoso-Loyo; Javier Cabiedes; Alejandro Orozco-Narváez; Luis Dávila-Maldonado; Yemil Atisha-Fregoso; Betty Diamond; Luis Llorente; Jorge Sánchez-Guerrero
Journal:  PLoS One       Date:  2008-10-06       Impact factor: 3.240

View more
  2 in total

1.  Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations.

Authors:  Rory C Monahan; Michelle D van den Beukel; Nicole V Borggreven; Rolf Fronczek; Tom W J Huizinga; Margreet Kloppenburg; Gerda M Steup-Beekman; Leendert A Trouw
Journal:  RMD Open       Date:  2022-04

2.  Brain-Reactive Antibodies are Potential Biomarkers for Evaluating Therapeutic Efficacy in NPSLE Patients.

Authors:  Xiujiao Wang; Dongju Feng; Yao Ke; Lei Gu; Chengyin Lv; Miaojia Zhang; Qiang Wang; Yanyan Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-04       Impact factor: 2.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.